Answers are grounded in this paper and cite their sources.
In vitro study reveals potent acetylcholinesterase inhibition by novel benzimidazole-isatin hybrids, highlighting their potential as therapeutic candidates for Alzheimer's disease.
Objective: A novel series of benzimidazole–isatin hybrid compounds was designed and synthesized to evaluate their inhibitory activity against acetylcholinesterase (AChE) and establish comprehensive structure–activity relationships (SAR). Methods: Target hybrids and intermediate precursors were synthesized using both conventional heating and microwave-assisted protocols. Structural elucidation of all synthesized compounds was unequivocally performed using 1H, 13C NMR, high-resolution mass spectrometry (HRMS), and elemental analysis. Results and Discussion: Biological evaluation revealed that integration of the isatin scaffold significantly enhanced AChE inhibitory potency compared with that of the isatin-free intermediate precursors. Notably, several hybrid derivatives displayed superior inhibitory activity relative to the reference drug galantamine (IC50 = 56.4 ± 0.7 µM). SAR analysis demonstrated that electron-withdrawing substituents on the benzyl moiety, in synergy with halogenation on the isatin ring, substantially boosted AChE inhibition. Conclusions: This study underscores microwave irradiation as a highly efficient and superior synthetic approach, establishing benzimidazole–isatin hybrids—most notably compound Vi—as promising pharmacophoric scaffolds for drug development targeting Alzheimer’s disease.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: